Barely Significant

Excerpts

514,629 sentences

an increasing trendp = 0.0190.4× alphagold
The relative abundances of Bacteroidota, Proteobacteria, and Spirochaetes were lower in the RT group than in the CON group, with a decrease observed in Bacteroidota in the RT group on days 7 and 28 after rumen fluid transplantation ( p = 0.013), while Proteobacteria showed a decreasing trend in the CON group and an increasing trend in RT; however, this was only at day 4 ( p = 0.019).
a significant trendp = 0.01960.4× alphagold
In the case of PRELID1 , there was a significant trend (R = 0.3932; p = 0.0196) towards higher copy number assignments for samples with DNA input amounts above the average (13.28 ng; range 2–120 ng) of the sample set ( Figure 3 ), even after removing outliers (>75 ng input DNA).
highly significantP = 0.01960.4× alphaqualifiedgold
Response of biological traits The global testing procedure (a multivariate statistic equivalent to the sum of eigenvalues from RLQ analysis) was highly significant ( P = 0.0196 for Model 2 and P = 0.0192 for Model 4), suggesting a globally significant correlation between biological traits and environmental variables (Fig. 6 ).
highly significantp = 0.01970.4× alphaqualifiedgold
Similar effects of VNS were observed in the intact hemispheres contralateral to the infusion sites: a two-way ANOVA on fiber crossings in contralesional M1 revealed a highly significant effect of VNS, as well as a significant effect of 6-OHDA treatment (contralesional M1 TH+ fiber counts, two-way ANOVA; 6-OHDA vs. veh: F = 6.42, p = 0.0197; VNS vs. sham: F = 38.82, p < 0.000; interaction: F = 0.07, p = 0.798).
The higher BiP expression in the MU group was also supported by western blotting analysis, although the difference of the BiP/FLAG ratio did not reach statistical significance, probably due to the inclusion of FLAG-negative cells (BiP/FLAG, WT vs MU: P = 0.0198; BiP/Acitn, WT-H 2 O 2 vs MU-H 2 O 2 : P = 0.0102; Figure 4D ).
showed a trendP = 0.01990.4× alpha
Post hoc analysis demonstrated that favipiravir-treated patients showed a trend toward clinical improvement at day 7 among those with moderate COVID-19 (71.43% vs 55.86%, 95% CI: 0.0271 to 0.2843, P = 0.0199) and earlier resolution of fever and cough (p < 0.0001).
Favipiravir: A new and emerging antiviral option in COVID-19.
Med J Armed Forces India · 2020 · PMC7467067